{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T08:48:22Z","timestamp":1794386902624,"version":"4.9.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCI Cancer Center Support Grant,"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Metastatic uveal melanoma (mUM) is an aggressive cancer with limited treatment options; 85\u221290% of tumors harbor activating\n                    <jats:italic>GNAQ<\/jats:italic>\n                    and\n                    <jats:italic>GNA11<\/jats:italic>\n                    mutations. Uveal melanoma cells also express PMEL (also known as PMEL17 or gp100), a melanocyte lineage antigen. DYP688, a novel biology-matched antibody\u2212drug conjugate, binds surface PMEL and delivers the potent G\u03b1\n                    <jats:sub>q<\/jats:sub>\n                    \/G\u03b1\n                    <jats:sub>11<\/jats:sub>\n                    (G\n                    <jats:sub>q\/11<\/jats:sub>\n                    ) inhibitor SDZ475 as payload by internalization. This dose-escalating first-in-human phase 1 study of DYP688 in patients with metastatic uveal melanoma and other\n                    <jats:italic>GNAQ<\/jats:italic>\n                    \/\n                    <jats:italic>GNA<\/jats:italic>\n                    <jats:italic>11<\/jats:italic>\n                    -mutant melanomas assessed safety as the primary endpoint and pharmacokinetics and preliminary antitumor activity as secondary endpoints. Sixty-six patients received varying DYP688 doses and schedules. Grade 3 treatment-related adverse events occurred in five patients (7.6%), including one dose-limiting toxicity of grade 3 hypotension. Objective responses were seen in 13 out of 66 patients (19.7%) and tumor reduction in 47 out of 66 patients (71.2%). Median progression-free survival was 7.2 (95% CI: 5.3\u20137.8) months. In summary, DYP688 was well tolerated and showed preliminary efficacy, supporting this novel therapeutic approach. ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05415072\" ext-link-type=\"uri\">NCT05415072<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04518-z","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:01:35Z","timestamp":1783933295000},"page":"3248-3258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An anti-PMEL antibody\u2212drug conjugate with a Gq\/11 inhibitor payload in GNAQ\/GNA11-mutant melanomas: a phase 1 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7861-4104","authenticated-orcid":false,"given":"Matteo S.","family":"Carlino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-6426","authenticated-orcid":false,"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Piperno-Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Gromke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4685-1666","authenticated-orcid":false,"given":"Damien","family":"Kee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8262-8608","authenticated-orcid":false,"given":"Egle","family":"Ramelyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-4412","authenticated-orcid":false,"given":"Alexander N.","family":"Shoushtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3290-9959","authenticated-orcid":false,"given":"Alexander Z.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-421X","authenticated-orcid":false,"given":"Alexander","family":"Enk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor E.","family":"Handel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3693-5994","authenticated-orcid":false,"given":"Kamaneh","family":"Montazeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ramon-Patino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Richly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-0802","authenticated-orcid":false,"given":"Manuel","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-4475","authenticated-orcid":false,"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3126-1193","authenticated-orcid":false,"given":"James","family":"Smithy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M.","family":"Speetjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Milanez-Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwesha","family":"Chaudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Hoffmaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Ising","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier A.","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiruvamoor","family":"RamKumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4703-6388","authenticated-orcid":false,"given":"Aimee","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6259-4369","authenticated-orcid":false,"given":"Sherif","family":"Sharaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmaja","family":"Yerramilli-Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-829X","authenticated-orcid":false,"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"4518_CR1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.aopr.2024.10.001","volume":"4","author":"X Hou","year":"2024","unstructured":"Hou, X. et al. Global incidence and prevalence in uveal melanoma. Adv. Ophthalmol. Pract. Res. 4, 226\u2013232 (2024).","journal-title":"Adv. Ophthalmol. Pract. Res."},{"key":"4518_CR2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","volume":"127","author":"CL Shields","year":"2009","unstructured":"Shields, C. L. et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch. Ophthalmol. 127, 989\u2013998 (2009).","journal-title":"Arch. Ophthalmol."},{"key":"4518_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/ceo.14214","volume":"51","author":"H Bai","year":"2023","unstructured":"Bai, H., Bosch, J. J. & Heindl, L. M. Current management of uveal melanoma: a review. Clin. Exp. Ophthalmol. 51, 484\u2013494 (2023).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"4518_CR4","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.ajo.2005.05.034","volume":"140","author":"DN Hu","year":"2005","unstructured":"Hu, D. N., Yu, G. P., McCormick, S. A., Schneider, S. & Finger, P. T. Population-based incidence of uveal melanoma in various races and ethnic groups. Am. J. Ophthalmol. 140, 612\u2013617 (2005).","journal-title":"Am. J. Ophthalmol."},{"key":"4518_CR5","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ophtha.2007.01.032","volume":"114","author":"G Virgili","year":"2007","unstructured":"Virgili, G. et al. Incidence of uveal melanoma in Europe. Ophthalmology 114, 2309\u20132315 (2007).","journal-title":"Ophthalmology"},{"key":"4518_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ijc.11057","volume":"105","author":"CM Vajdic","year":"2003","unstructured":"Vajdic, C. M. et al. Incidence of ocular melanoma in Australia from 1990 to 1998. Int. J. Cancer 105, 117\u2013122 (2003).","journal-title":"Int. J. Cancer"},{"key":"4518_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000480640","volume":"4","author":"ME Aronow","year":"2018","unstructured":"Aronow, M. E., Topham, A. K. & Singh, A. D. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973\u22122013). Ocul. Oncol. Pathol. 4, 145\u2013151 (2018).","journal-title":"Ocul. Oncol. Pathol."},{"key":"4518_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","volume":"20","author":"RD Carvajal","year":"2023","unstructured":"Carvajal, R. D. et al. Advances in the clinical management of uveal melanoma. Nat. Rev. Clin. Oncol. 20, 99\u2013115 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4518_CR9","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","volume":"123","author":"M Diener-West","year":"2005","unstructured":"Diener-West, M. et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch. Ophthalmol. 123, 1639\u20131643 (2005).","journal-title":"Arch. Ophthalmol."},{"key":"4518_CR10","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.3390\/cancers15205025","volume":"15","author":"YS Ye\u015filta\u015f","year":"2023","unstructured":"Ye\u015filta\u015f, Y. S., Zabor, E. C., Wrenn, J., Oakey, Z. & Singh, A. D. Surveillance for metastasis in high-risk uveal melanoma patients: standard versus enhanced protocols. Cancers 15, 5025 (2023).","journal-title":"Cancers"},{"key":"4518_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3390\/cancers18010121","volume":"18","author":"J Alban","year":"2026","unstructured":"Alban, J. et al. Metastatic uveal melanoma surveillance: a Delphi panel consensus. Cancers 18, 121 (2026).","journal-title":"Cancers"},{"key":"4518_CR12","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","volume":"30","author":"L Khoja","year":"2019","unstructured":"Khoja, L. et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann. Oncol. 30, 1370\u20131380 (2019).","journal-title":"Ann. Oncol."},{"key":"4518_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","volume":"29","author":"ES Rantala","year":"2019","unstructured":"Rantala, E. S., Hernberg, M. & Kivela, T. T. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 29, 561\u2013568 (2019).","journal-title":"Melanoma Res."},{"key":"4518_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","volume":"6","author":"MJ Jager","year":"2020","unstructured":"Jager, M. J. et al. Uveal melanoma. Nat. Rev. Dis. Primers 6, 24 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"4518_CR15","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.3390\/cancers14133066","volume":"14","author":"P Silva-Rodr\u00edguez","year":"2022","unstructured":"Silva-Rodr\u00edguez, P. et al. GNAQ and GNA11 genes: a comprehensive review on oncogenesis, prognosis and therapeutic opportunities in uveal melanoma. Cancers 14, 3066 (2022).","journal-title":"Cancers"},{"key":"4518_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","volume":"101","author":"RD Carvajal","year":"2017","unstructured":"Carvajal, R. D. et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br. J. Opthalmol. 101, 38\u201344 (2017).","journal-title":"Br. J. Opthalmol."},{"key":"4518_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100403","volume":"296","author":"MD Onken","year":"2021","unstructured":"Onken, M. D. et al. Targeting primary and metastatic uveal melanoma with a G protein inhibitor. J. Biol. Chem. 296, 100403 (2021).","journal-title":"J. Biol. Chem."},{"key":"4518_CR18","doi-asserted-by":"crossref","unstructured":"Wk, J. et al. Abstract IA022: DYP688, a first-in-class PMEL17-targeted antibody drug conjugate delivering a Gq\/11-specific inhibitor for the treatment of metastatic uveal melanoma. Mol. Cancer Ther. 23, IA022 (2024).","DOI":"10.1158\/1538-8514.CANCERCHEM24-IA022"},{"key":"4518_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s002620050379","volume":"44","author":"SN Wagner","year":"1997","unstructured":"Wagner, S. N. et al. Analysis of PMEL17\/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy. Cancer Immunol. Immunother. 44, 239\u2013247 (1997).","journal-title":"Cancer Immunol. Immunother."},{"key":"4518_CR20","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-15-2294","volume":"22","author":"LD Rothermel","year":"2016","unstructured":"Rothermel, L. D. et al. Identification of an immunogenic subset of metastatic uveal melanoma. Clin. Cancer Res. 22, 2237\u20132249 (2016).","journal-title":"Clin. Cancer Res."},{"key":"4518_CR21","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1242\/jcs.02804","volume":"119","author":"JC Valencia","year":"2006","unstructured":"Valencia, J. C. et al. Sorting of PMEL17 to melanosomes through the plasma membrane by AP1 and AP2: evidence for the polarized nature of melanocytes. J. Cell Sci. 119, 1080\u20131091 (2006).","journal-title":"J. Cell Sci."},{"key":"4518_CR22","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1200\/JCO.21.01805","volume":"40","author":"RD Carvajal","year":"2022","unstructured":"Carvajal, R. D. et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J. Clin. Oncol. 40, 1939\u20131948 (2022).","journal-title":"J. Clin. Oncol."},{"key":"4518_CR23","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel, J. C. et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 389, 2256\u20132266 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4518_CR24","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196\u20131206 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4518_CR25","first-page":"6561","volume":"52","author":"FM Marincola","year":"1992","unstructured":"Marincola, F. M. et al. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res. 52, 6561\u20136566 (1992).","journal-title":"Cancer Res."},{"key":"4518_CR26","unstructured":"Novartis Pharmaceuticals. A phase I\/II study of DYP688 in patients with metastatic uveal melanoma and other GNAQ\/11 mutant melanomas. https:\/\/clinicaltrials.gov\/study\/NCT05415072 (2025)."},{"key":"4518_CR27","doi-asserted-by":"publisher","first-page":"e26332","DOI":"10.1371\/journal.pone.0026332","volume":"6","author":"S Kraemer","year":"2011","unstructured":"Kraemer, S. et al. From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. PLoS ONE 6, e26332 (2011).","journal-title":"PLoS ONE"},{"key":"4518_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1126\/science.aaq1327","volume":"361","author":"V Emilsson","year":"2018","unstructured":"Emilsson, V. et al. Co-regulatory networks of human serum proteins link genetics to disease. Science 361, 769\u2013773 (2018).","journal-title":"Science"},{"key":"4518_CR29","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1021\/pr070021t","volume":"6","author":"M Pardo","year":"2007","unstructured":"Pardo, M. et al. Biomarker discovery from uveal melanoma secretomes: identification of gp100 and cathepsin D in patient serum. J. Proteome Res. 6, 2802\u20132811 (2007).","journal-title":"J. Proteome Res."},{"key":"4518_CR30","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.4143\/crt.2017.171","volume":"50","author":"D Lorenzo","year":"2018","unstructured":"Lorenzo, D. et al. Prognostic factors and decision tree for long-term survival in metastatic uveal melanoma. Cancer Res. Treat. 50, 1130\u20131139 (2018).","journal-title":"Cancer Res. Treat."},{"key":"4518_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53145-0","volume":"15","author":"M Rodrigues","year":"2024","unstructured":"Rodrigues, M. et al. Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp. Nat. Commun. 15, 8851 (2024).","journal-title":"Nat. Commun."},{"key":"4518_CR32","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jamaophthalmol.2015.1119","volume":"133","author":"MP Gupta","year":"2015","unstructured":"Gupta, M. P. et al. Clinical characteristics of uveal melanoma in patients with germline BAP1mutations. JAMA Ophthalmol 133, 881\u2013887 (2015).","journal-title":"JAMA Ophthalmol"},{"key":"4518_CR33","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/bjc.2014.417","volume":"111","author":"H Kalirai","year":"2014","unstructured":"Kalirai, H., Dodson, A., Faqir, S., Damato, B. E. & Coupland, S. E. Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing. Br. J. Cancer 111, 1373\u20131380 (2014).","journal-title":"Br. J. Cancer"},{"key":"4518_CR34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.joco.2018.02.005","volume":"30","author":"B Masoomian","year":"2018","unstructured":"Masoomian, B., Shields, J. A., Shields, C. L. & Shields Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J. Curr. Ophthalmol. 30, 102\u2013109 (2018).","journal-title":"J. Curr. Ophthalmol."},{"key":"4518_CR35","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1158\/1535-7163.MCT-12-1020","volume":"12","author":"G Ambrosini","year":"2013","unstructured":"Ambrosini, G., Musi, E., Ho, A. L., de Stanchina, E. & Schwartz, G. K. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Mol. Cancer Ther. 12, 768\u2013776 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"4518_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1232787","volume":"14","author":"L Cao","year":"2023","unstructured":"Cao, L. et al. Darovasertib, a novel treatment for metastatic uveal melanoma. Front. Pharmacol. 14, 1232787 (2023).","journal-title":"Front. Pharmacol."},{"key":"4518_CR37","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.3390\/cancers13215504","volume":"13","author":"AN Shoushtari","year":"2021","unstructured":"Shoushtari, A. N. et al. A phase Ib study of sotrastaurin, a PKC inhibitor, and alpelisib, a PI3K\u03b1 inhibitor, in patients with metastatic uveal melanoma. Cancers 13, 5504 (2021).","journal-title":"Cancers"},{"key":"4518_CR38","doi-asserted-by":"publisher","first-page":"iii35","DOI":"10.1093\/annonc\/mdw304","volume":"27","author":"F Blackhall","year":"2016","unstructured":"Blackhall, F. & Cappuzzo, F. Crizotinib: from discovery to accelerated development to front\u2011line treatment. Ann. Oncol. 27, iii35\u2013iii41 (2016).","journal-title":"Ann. Oncol."},{"key":"4518_CR39","doi-asserted-by":"publisher","first-page":"S651","DOI":"10.1016\/j.annonc.2023.09.2215","volume":"34","author":"M Mckean","year":"2023","unstructured":"Mckean, M. et al. 1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM). Ann. Oncol. 34, S651 (2023).","journal-title":"Ann. Oncol."},{"key":"4518_CR40","doi-asserted-by":"publisher","first-page":"LBA9503","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA9503","volume":"44","author":"MM Orloff","year":"2026","unstructured":"Orloff, M. M. et al. Darovasertib plus crizotinib vs investigator\u2019s choice as first-line treatment for patients with HLA-A2\u2013negative metastatic uveal melanoma: primary results from the OptimUM-02 trial. J. Clin. Oncol. 44, LBA9503 (2026).","journal-title":"J. Clin. Oncol."},{"key":"4518_CR41","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-18-3382","volume":"25","author":"F Fai\u00e3o-Flores","year":"2019","unstructured":"Fai\u00e3o-Flores, F. et al. HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma. Clin. Cancer Res. 25, 5686\u20135701 (2019).","journal-title":"Clin. Cancer Res."},{"key":"4518_CR42","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1056\/NEJMoa1300253","volume":"368","author":"MA Nesbit","year":"2013","unstructured":"Nesbit, M. A. et al. Mutations affecting G\u2011protein subunit \u03b111 in hypercalcemia and hypocalcemia. N. Engl. J. Med. 368, 2476\u20132486 (2013).","journal-title":"N. Engl. J. Med."},{"key":"4518_CR43","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40123-024-00913-2","volume":"13","author":"J Wang","year":"2024","unstructured":"Wang, J., Li, Z. & Yin, H. The future of checkpoint inhibitors in uveal melanoma: a narrative review. Ophthalmol. Ther. 13, 1103\u20131123 (2024).","journal-title":"Ophthalmol. Ther."},{"key":"4518_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf173","volume":"30","author":"A Ciernik","year":"2025","unstructured":"Ciernik, A. et al. Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma. Oncologist 30, oyaf173 (2025).","journal-title":"Oncologist"},{"key":"4518_CR45","doi-asserted-by":"publisher","first-page":"e000331","DOI":"10.1136\/jitc-2019-000331","volume":"8","author":"YG Najjar","year":"2020","unstructured":"Najjar, Y. G. et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J. Immunother. Cancer 8, e000331 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"4518_CR46","first-page":"798","volume":"11","author":"J Dollar","year":"2023","unstructured":"Dollar, J. et al. Single cell analysis of phase II study of nivolumab and relatlimab in metastatic uveal melanoma reveals tumor and immune response to dual PD-1 and LAG-3 inhibition. J. Immunother. Cancer 11, 798\u2013798 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"4518_CR47","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1038\/s41417-022-00437-6","volume":"29","author":"CD Lietman","year":"2022","unstructured":"Lietman, C. D. & McKean, M. Targeting GNAQ\/11 through PKC inhibition in uveal melanoma. Cancer Gene Ther. 29, 1809\u20131813 (2022).","journal-title":"Cancer Gene Ther."},{"key":"4518_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0051-4","volume":"2","author":"MC Wagle","year":"2018","unstructured":"Wagle, M. C. et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis. Oncol. 2, 7 (2018).","journal-title":"NPJ Precis. Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04518-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04518-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04518-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:02:55Z","timestamp":1789480975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04518-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4518"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04518-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S.C. reports receiving honoraria from Bristol Myers Squibb, Merck Sharp & Dohme and Novartis and has consultancy\/advisory relationships with Amgen, Bristol Myers Squibb, Eisai, IDEAYA Biosciences, Innovent Biologics, Medison, Merck Serono, Moderna Therapeutics, Merck Sharp & Dohme, Nektar, Novartis, OncoSec, Pierre Fabre, QBiotics, Regeneron, Roche and Sanofi. E.K. has consultancy\/advisory relationships with Delcath, Immunocore and Bristol Myers Squibb (all paid to the institution) and has received research grants unrelated to the present work from Bristol Myers Squibb, Delcath, Novartis and Pierre Fabre (all paid to the institution). S.P.-N. has consultancy\/advisory relationships with Immunocore, IDEAYA Biosciences, Replimune and Pierre Fabre, unrelated to the present work. R.J.S. has consultancy\/advisory relationships with BridGene Biosciences, Bristol Myers Squibb, Marengo Therapeutics, Merck, Novartis, Pfizer and Replimune and has received research grants from Aeglea Biotherapeutics, Amgen, Asana Biosciences, BeiGene, BioMed Valley Discoveries, Compugen, Deciphera, Georgimmune, Lilly, Marengo Therapeutics, Merck, Moderna Therapeutics, Neon Therapeutics, Pfizer, Roche\/Genentech, Rubius Therapeutics, Sanofi, Strategia, Synthekine and Viralytics (all paid to the institution). These grants are unrelated to the present work. R.C. has consultancy\/advisory relationships with Caper Labs, Castle Biosciences, IDEAYA Biosciences, Immunocore, iOnctura, Mural Oncology, Pierre Fabre and Trisalus. R.D. reports receiving honoraria from Amgen, Bristol Myers Squibb, Catalym, MaxiVax, Merck Sharp & Dohme, Novartis, Oncobit, Pfizer, Pierre Fabre, Regeneron, Roche, Sanofi, Second Genome, Simcere, Sun Pharma, T3 Pharmaceuticals and Takeda and has consultancy\/advisory relationships with the same companies. R.D. has also received research funding from Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis and Roche (all paid to the institution). T.G., A.E., E.E.H., J.R.-P., H.R., F.M.S. and P.Y.-R. declare no competing interests. P.Y.-R. was an employee of Novartis when this study was conducted. K.M. has a consulting relationship with Delcath. J.C.H. reports receiving honoraria for talks from Amgen, Bristol Myers Squibb, Delcath, Immunocore, Merck Sharp & Dohme, Novartis, Pierre Fabre, Replimune, Sanofi and Sun Pharma; honoraria for advisory board participation from Sun Pharma, Bristol Myers Squibb, Immunocore, Merck Sharp & Dohme, Novartis, Philogen, Pierre Fabre and Sanofi (paid to the institution); and payments for patient treatment in clinical trials (paid to the institution) from BioNTech, Bristol Myers Squibb, Genentech\/Roche, Genmab, Immatics, Immunocore, IOBiotech, Iovance Biotherapeutics, Merck Sharp & Dohme, Novartis, Philogen, Pfizer, Pierre Fabre, Regeneron, Replimune and Sanofi. D.K. has consultancy\/advisory relationships with Bristol Myers Squibb\/Celgene, Medison, Merck Sharp & Dohme and Novartis. E.R. reports receiving honoraria from Bristol Myers Squibb GmbH & Co. KG, Galderma, Lilly, Merck Sharp & Dohme, Pierre Fabre and Sanofi; has consultancy\/advisory relationships with Amgen, Kyowa Kirin International and Sanofi\/Regeneron; is on speakers\u2019 bureaus for Bristol Myers Squibb GmbH & Co. KG, Merck Sharp & Dohme and Sanofi\/Regeneron; has received research funding from Amgen and Sanofi\/Regeneron (paid to the institution); has intellectual property from contributions to UpToDate; and has received travel support from Amgen, Pierre Fabre and Sanofi. A.N.S. has consultancy\/advisory relationships with Novartis, Mural Oncology, Immunocore, Erasca, Replimune, Iovance Biotherapeutics and Innovent and institutional support for trials from Novartis (the present work), Bristol Myers Squibb, Immunocore, Targovax, Pfizer, Mural Oncology, IDEAYA Biosciences, Checkmate Pharmaceuticals, Foghorn Therapeutics, Linnaeus Therapeutics, Iovance Biotherapeutics, Obsidian Therapeutics, Replimune and Ionctura (outside the present work). A.Z.W. has received research funding from IDEAYA Biosciences, Novartis and Regeneron (paid to the institution). M.R. has consultancy\/advisory relationships with Immunocore, AbbVie, GlaxoSmithKline and AstraZeneca; has received research grants unrelated to the present work from Johnson & Johnson, Merck and Daiichi Sankyo; and has received travel funding from AbbVie and Immunocore. S. Sandhu served in advisory roles for AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Merck Healthcare, Novartis, Janssen, Skyline Diagnostics, AdvanCell, Daiichi Sankyo, Synolo Therapeutics, Macrogenics, ERASCA and AbbVie; received honoraria from Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Janssen, AdvanCell and Skyline Diagnostics (all paid to institution); received research funding from Amgen, AstraZeneca, Merck Sharp & Dohme, Merck Healthcare, Endocyte (Novartis), Roche\/Genentech, Pfizer and Senhwa Biosciences (all paid to institution); and owns stock in AdvanCell. J.S. has consultancy\/advisory relationships with Bristol Myers Squibb, Daiichi Sankyo and Iovance Biotherapeutics; has received research grants from IO Biotech, Daiichi Sankyo, Regeneron and Immatics (all paid to institution); and has received travel funding from Immatics. P.M.-A., A.C., K.H., M.I., T.R., A.R., S. Sharaby, J.A.O. and L.W. are Novartis employees. J.A.O., A.R., T.R. and A.C. hold Novartis shares or restricted stock units. E.C. is an employee of START and HM Hospitales; has consulting or advisory roles at Adcendo, Amunix, Anaveon, AstraZeneca\/MedImmune, Bristol Myers Squibb, Chugai Pharma, Diaccurate, Elevation Oncology, Ellipses Pharma, Genmab, Janssen-Cilag, MonTa Biosciences, MSD Oncology, Nanobiotix, Nouscom, Novartis, OncoDNA, PharmaMar, Roche\/Genentech, Servier, TargImmune Therapeutics, T-Knife Therapeutics and Syneos Health; and has leadership roles in BeiGene, the European Organisation for Research and Treatment of Cancer (EORTC), Merus NV, Novartis, PharmaMar, Sanofi and START. E.C. has other relationships with the CRIS Cancer Foundation, Foundation PharmaMar and Investigational Therapeutics in Oncological Sciences and has stock and other ownership interests in HM Hospitales, Oncoart Associated and START.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}